Document Detail

The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study.
MedLine Citation:
PMID:  20963405     Owner:  NLM     Status:  In-Process    
OBJECTIVES: This prospective, open-label multicenter study was conducted to assess the pharmacokinetics of Biolimus A9 after elution from BioMatrix II coronary stents. Recent clinical trials have demonstrated the efficacy and safety of Biolimus A9 eluted from different stent platforms. To date, the pharmacokinetics of Biolimus A9 in patients following the deployment of BioMatrix II stents has not yet been studied
METHODS: BioMatrix II stents were implanted into 27 patients with coronary artery disease. The primary endpoints of the study were the systemic concentrations of Biolimus A9 after 28 days and 6 months as measured using a sensitive validated liquid chromatography-tandem mass spectrometry assay.
RESULTS: The highest measured blood concentration at any time point was 394 pg/mL. At 28 days and 6 months following stent placement, 51.8 and 100% of patients, respectively, had Biolimus A9 concentrations <10 pg/mL. After 9 months, 100% of the patients were free of major cardiac adverse events (MACE). There was no Biolimus A9 toxicity, no cardiac or non-cardiac deaths, no myocardial infarctions, nor target vessel or target lesion revascularizations during the 9 months of follow-up. No case of acute, subacute, or late stent thrombosis was detected.
CONCLUSIONS: Compared to other drug-eluting stents, such as Cypher, BioMatrix II results in relatively low systemic exposure, which may be explained by the ablominal coating of the Biomatrix II stent in combination with Biolimus A9's high lipophilicity.
Miodrag C Ostojic; Zoran Perisic; Dragan Sagic; Robert Jung; Yan-Ling Zhang; Jamie Bendrick-Peart; Ronald Betts; Uwe Christians;
Related Documents :
17493695 - Percutaneous coronary intervention with stenting of left main coronary artery with drug...
2532065 - Uneven host tissue ongrowth and tissue detachment in stent mounted heart valve allograf...
15254645 - Robot-assisted cardiac surgery.
10555595 - Interventional cardiac catheterization advances in nonsurgical approaches to congenital...
14520315 - Interruption of cardiopulmonary resuscitation with the use of the automated external de...
16368845 - Partial sensory and motor deficit of ipsilateral lower limb after continuous interscale...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-10-09
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  67     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  389-98     Citation Subset:  IM    
Medical School, University of Belgrade and Clinical Center of Serbia, Division of Cardiology, Dr Subotic street 8, 11000, Belgrade, Serbia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
M Ostojic / ; M Nedeljkovic / ; S Stojkovic / ; B Beleslin / ; D Orlic / ; M Tomasevic / ; A Arandjelovic / ; Z Perisic / ; S Apostolovic / ; M Pavlovic / ; D Sagic / ; B Milosavljevic / ; L J Mangovski / ; Z Antonic / ; M Colic / ; D Topic / ; L Angelkov / ; R Jung / ; D Benz / ; D Debeljacki / ; V Ivanovic / ; D Bikicki /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose vala...
Next Document:  Dimethyl sulfoxide with lignocaine versus eutectic mixture of local anesthetics: prospective randomi...